These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 24477727)

  • 1. Transcultural adaptation of the "EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)" into Brazilian Portuguese.
    Serrano EV; Valim V; Miyamoto ST; Giovelli RA; Paganotti MA; Cadê NV
    Rev Bras Reumatol; 2013; 53(6):483-93. PubMed ID: 24477727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of fatigue and dryness in primary Sjögren's syndrome: Brazilian version of "Profile of Fatigue and Discomfort - Sicca Symptoms Inventory (short form) (PROFAD-SSI-SF)".
    Miyamoto ST; Paganotti MA; Serrano ÉV; Giovelli RA; Valim V
    Rev Bras Reumatol; 2015; 55(2):113-22. PubMed ID: 25582994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation and psychometric properties of the Eular Sjögren's Syndrome Patient Reported Index (ESSPRI) into Brazilian Portuguese.
    Paganotti MA; Valim V; Serrano ÉV; Miyamoto ST; Giovelli RA; Santos MC
    Rev Bras Reumatol; 2015; 55(5):439-45. PubMed ID: 26345467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
    Meiners PM; Arends S; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
    Ann Rheum Dis; 2012 Aug; 71(8):1297-302. PubMed ID: 22258489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI).
    Seror R; Theander E; Brun JG; Ramos-Casals M; Valim V; Dörner T; Bootsma H; Tzioufas A; Solans-Laqué R; Mandl T; Gottenberg JE; Hachulla E; Sivils KL; Ng WF; Fauchais AL; Bombardieri S; Valesini G; Bartoloni E; Saraux A; Tomsic M; Sumida T; Nishiyama S; Caporali R; Kruize AA; Vollenweider C; Ravaud P; Vitali C; Mariette X; Bowman SJ;
    Ann Rheum Dis; 2015 May; 74(5):859-66. PubMed ID: 24442883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index: a complete picture of primary Sjögren's syndrome patients.
    Seror R; Gottenberg JE; Devauchelle-Pensec V; Dubost JJ; Le Guern V; Hayem G; Fauchais AL; Goeb V; Hachulla E; Hatron PY; Larroche C; Morel J; Pedriger A; Puechal X; Rist S; Saraux A; Sene D; Sibilia J; Vittecoq O; Zarnitsky C; Labetoulle M; Ravaud P; Mariette X
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1358-64. PubMed ID: 23436737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome measures for primary Sjögren's syndrome: a comprehensive review.
    Seror R; Theander E; Bootsma H; Bowman SJ; Tzioufas A; Gottenberg JE; Ramos-Casals M; Dörner T; Ravaud P; Mariette X; Vitali C
    J Autoimmun; 2014 Jun; 51():51-6. PubMed ID: 24411404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of ESSDAI and ClinESSDAI in potential optimisation of trial outcomes in primary Sjögren's syndrome: examination of data from the UK Primary Sjögren's Syndrome Registry.
    Dumusc A; Ng WF; James K; Griffiths B; Price E; Pease C; Emery P; Lanyon P; Jones A; Bombardieri M; Sutcliffe N; Pitzalis C; Gupta M; McLaren J; Cooper A; Giles I; Isenberg D; Saravanan V; Coady D; Dasgupta B; McHugh N; Young-Min S; Moots R; Gendi N; Akil M; Barone F; Fisher B; Rauz S; Richards A; Bowman S
    Swiss Med Wkly; 2018; 148():w14588. PubMed ID: 29442344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease activity and damage in patients with primary Sjogren's syndrome: Prognostic value of salivary gland ultrasonography.
    Milic V; Colic J; Cirkovic A; Stanojlovic S; Damjanov N
    PLoS One; 2019; 14(12):e0226498. PubMed ID: 31891590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sjögren's Systemic Clinical Activity Index (SCAI)--a systemic disease activity measure for use in clinical trials in primary Sjögren's syndrome.
    Bowman SJ; Sutcliffe N; Isenberg DA; Goldblatt F; Adler M; Price E; Canavan A; Hamburger J; Richards A; Rauz S; Regan M; Gadsby K; Rigby S; Jones A; Mathew R; Mulherin D; Stevenson A; Nightingale P
    Rheumatology (Oxford); 2007 Dec; 46(12):1845-51. PubMed ID: 18032543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome.
    Seror R; Ravaud P; Bowman SJ; Baron G; Tzioufas A; Theander E; Gottenberg JE; Bootsma H; Mariette X; Vitali C;
    Ann Rheum Dis; 2010 Jun; 69(6):1103-9. PubMed ID: 19561361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry).
    Ramos-Casals M; Brito-Zerón P; Solans R; Camps MT; Casanovas A; Sopeña B; Díaz-López B; Rascón FJ; Qanneta R; Fraile G; Pérez-Alvarez R; Callejas JL; Ripoll M; Pinilla B; Akasbi M; Fonseca E; Canora J; Nadal ME; de la Red G; Fernández-Regal I; Jiménez-Heredia I; Bosch JA; Ayala MD; Morera-Morales L; Maure B; Mera A; Ramentol M; Retamozo S; Kostov B; ;
    Rheumatology (Oxford); 2014 Feb; 53(2):321-31. PubMed ID: 24162151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of systemic activity of pediatric primary Sjögren's syndrome by EULAR Sjögren's syndrome disease activity index (ESSDAI).
    Kobayashi I; Okura Y; Ueki M; Tozawa Y; Takezaki S; Yamada M; Ariga T
    Mod Rheumatol; 2019 Jan; 29(1):130-133. PubMed ID: 29529894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accurate detection of changes in disease activity in primary Sjögren's syndrome by the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index.
    Seror R; Mariette X; Bowman S; Baron G; Gottenberg JE; Bootsma H; Theander E; Tzioufas A; Vitali C; Ravaud P;
    Arthritis Care Res (Hoboken); 2010 Apr; 62(4):551-8. PubMed ID: 20391511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial.
    Bowman SJ; Fox R; Dörner T; Mariette X; Papas A; Grader-Beck T; Fisher BA; Barcelos F; De Vita S; Schulze-Koops H; Moots RJ; Junge G; Woznicki JN; Sopala MA; Luo WL; Hueber W
    Lancet; 2022 Jan; 399(10320):161-171. PubMed ID: 34861168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brazilian version of the "Primary Sjögren's Syndrome - Quality of Life questionnaire (PSS-QoL)": translation, cross-cultural adaptation and validation.
    Miyamoto ST; Serrano ÉV; Gianórdoli APE; Altoé LB; Noronha BD; Dos Santos PHA; Pedrini APT; da Silva NRS; Favarato LF; Alochio LV; Tomé WA; Lackner A; Valim V
    Adv Rheumatol; 2024 Aug; 64(1):60. PubMed ID: 39160602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI).
    Seror R; Bootsma H; Saraux A; Bowman SJ; Theander E; Brun JG; Baron G; Le Guern V; Devauchelle-Pensec V; Ramos-Casals M; Valim V; Dörner T; Tzioufas A; Gottenberg JE; Solans Laqué R; Mandl T; Hachulla E; Sivils KL; Ng WF; Fauchais AL; Bombardieri S; Priori R; Bartoloni E; Goeb V; Praprotnik S; Sumida T; Nishiyama S; Caporali R; Kruize AA; Vollenweider C; Ravaud P; Meiners P; Brito-Zerón P; Vitali C; Mariette X;
    Ann Rheum Dis; 2016 Feb; 75(2):382-9. PubMed ID: 25480887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial.
    Cornec D; Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Yves Hatron P; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Saliou P; Pers JO; Seror R; Saraux A
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):528-535. PubMed ID: 27390310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical applicability of the EULAR Sjogren's syndrome disease activity index: a cumulative ESSDAI score adds in describing disease severity.
    Risselada AP; Kruize AA; Bijlsma JW
    Ann Rheum Dis; 2012 Apr; 71(4):631. PubMed ID: 22219139
    [No Abstract]   [Full Text] [Related]  

  • 20. ESSPRI and other patient-reported indices in patients with primary Sjogren's syndrome during 100 consecutive outpatient visits at one rheumatological clinic.
    Pertovaara M; Korpela M
    Rheumatology (Oxford); 2014 May; 53(5):927-31. PubMed ID: 24464708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.